What was Akums Drugs's revenue in Q3 FY26?

Akums Drugs reported revenue of ₹1,160 Cr in Q3 FY26, a +14.8% change year-over-year.

Did Akums Drugs management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

AKUMSDRUGSPHARMACEUTICAL Healthcare 26 Jan 2026

Akums Drugs & Pharmaceuticals Ltd — Q3 FY26

Q: What guidance did Akums Drugs management give?

Q4 FY26 double-digit volume growth in CDMO: Management expects continued double-digit volume growth in CDMO for Q4 FY26 based on current visibility.

Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in international branded formulations.

Revenue ₹1,160 Cr +14.8%

EBITDA ₹147 Cr +21%

PAT ₹68 Cr +2.1%

EBITDA Margin 12.7% +65bps

Duration 54 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in international branded formulations. EBITDA margin expanded 65 bps YoY to 12.7%, aided by operating leverage and cost controls. PAT grew 2.1% to ₹68 crore, impacted by a one-time labor code charge of ₹18.2 crore. Management highlighted broad-based volume growth across therapies and channels, with Q4 also expected to see double-digit volume growth. Key growth drivers include the EU CDMO contract (€35M annual run-rate from FY28) and Zambia project ($25M supplies from H1 FY27). Risks include sustained API pricing pressure and potential delays in regulatory approvals for new facilities.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

⚖Claim Ledger 88% answered

Did management answer the analysts?

12 analyst questions audited.

View Claim Ledger →

!Risks 4 risks

Risk Intelligence

Sustained API pricing pressure

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

CDMO Revenue ₹916 Cr

+16.3% YoY

CDMO segment revenue grew 16.3% YoY driven by double-digit volume growth across existing customers.

CDMO EBITDA ₹126 Cr

+3.7% YoY

CDMO EBITDA increased 3.7% YoY; margins improved sequentially due to operating leverage.

International Branded Revenue ₹50 Cr

+18% YoY

International branded formulation revenue grew 18% YoY, with gross margins expanding from 25% to 35%.

API Revenue ₹54 Cr

+35.4% YoY

API revenue grew 35.4% YoY but remained loss-making; losses reduced to ₹7 Cr from ₹11 Cr last year.

Fast read

Guidance and risk preview

Top guidance Q4 FY26 double-digit volume growth in CDMO

Management expects continued double-digit volume growth in CDMO for Q4 FY26 based on current visibility.

Top risk Sustained API pricing pressure

API business continues to face pricing softness across key molecules, though the pace of decline has moderated.

View Risks →